CD79B Y196 mutation is a potent predictive marker for favorable response to R‐MPV in primary central nervous system lymphoma

• Published in: Cancer medicine (Malden, MA) MA), 2023-03, Vol.12 (6), p.7116-7126
• Main Authors: Yamaguchi, Junya, Ohka, Fumiharu, Lushun, Chalise, Motomura, Kazuya, Aoki, Kosuke, Takeuchi, Kazuhito, Nagata, Yuichi, Ito, Satoshi, Mizutani, Nobuhiko, Ohno, Masasuke, Suzaki, Noriyuki, Takasu, Syuntaro, Seki, Yukio, Kano, Takahisa, Wakabayashi, Kenichi, Oyama, Hirofumi, Kurahashi, Shingo, Tanahashi, Kuniaki, Hirano, Masaki, Shimizu, Hiroyuki, Kitano, Yotaro, Maeda, Sachi, Yamazaki, Shintaro, Wakabayashi, Toshihiko, Kondo, Yutaka, Natsume, Atsushi, Saito, Ryuta
• Format: Article
• Language: English
• Subjects: Brain cancer; Cancer therapies; CD79 Antigens - genetics; CD79B; Central nervous system; Central Nervous System - metabolism; Central Nervous System - pathology; Central Nervous System Neoplasms - drug therapy; Central Nervous System Neoplasms - genetics; Chemotherapy; Genotyping; Hospitals; Humans; Induction therapy; Lymphoma; Lymphoma, Large B-Cell, Diffuse - drug therapy; Medical prognosis; Methotrexate; Methotrexate - therapeutic use; Mutation; MYD88; MyD88 protein; Myeloid Differentiation Factor 88 - genetics; Myeloid Differentiation Factor 88 - metabolism; Nervous system; Neurotoxicity; Patients; primary central nervous system lymphoma; Procarbazine; Prognosis; Quality of life; Radiation therapy; rapid molecular diagnosis; Regression analysis; Rituximab; Rituximab - therapeutic use; R‐MPV; Survival; Thermal cycling; Tomography; Vincristine
• ISSN: 2045-7634; 2045-7634
• DOI: 10.1002/cam4.5512

Background Rituximab, high‐dose methotrexate (HD‐MTX), procarbazine and vincristine (R‐MPV), has significantly prolonged the survival of patients with primary central nervous system lymphoma (PCNSL), but predictive factors for response to R‐MPV have not yet been investigated. Herein, we investigated the correlation of MYD88 L265P and CD79B Y196 mutations, which are the most frequently found molecular alterations in PCNSL, with prognosis of patients with PCNSL treated with R‐MPV. Methods We investigated the long‐term clinical course and status of MYD88 and CD79B genes in 85 patients with PCNSL treated with R‐MPV or HD‐MTX treatment, and the correlation of these genetic mutations with prognosis. Results R‐MPV achieved an excellent tumor control rate (61.6% and 69.9% of 5‐year progression‐free and overall survival rates, respectively). While MYD88 L265P mutation had no significant effect on survival, patients with CD79B Y196 mutations exhibited prolonged survival (p